NCT02479308

A Study to Evaluate the Effect of ALKS 5461 on QT Intervals in Healthy Volunteers

The Effect of ALKS 5461 on QT Intervals in Healthy Volunteers

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 129 (actual)
• Sponsor: Alkermes, Inc. · Industry
• Sex: All
• Age: 18 Years – 50 Years
• Healthy volunteers: Accepted

Summary

This study will evaluate the effects of ALKS 5461 on QT intervals in healthy volunteers as well as evaluate the safety and tolerability of ALKS 5461.

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	Moxifloxacin	Single administration
DRUG	ALKS 5461	Daily administration for a total of 12 dosing days
DRUG	Placebo	Placebo will be matched to Moxifloxacin or ALKS 5461

Timeline

• Start date: 2015-06-01
• Primary completion: 2015-10-01
• Completion: 2015-10-01
• First posted: 2015-06-24
• Last updated: 2015-11-23

Locations

1 site across 1 country: United States